0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Igene Biotechnology
Its shares trade under the ticker IGNE. It has been listed since 29 July 1986. In the fiscal year to 31 December 2009, it reported revenue of $4.0m and a net loss of $140,747. At that date it held total assets of $4.8m and shareholders' equity of −$2.7m.
IGENE Biotechnology, Inc. engages in the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company is headquartered in Columbia, Maryland. The firm develops, produces and markets specialty biochemical products. The company is a supplier of natural astaxanthin, a nutrient in different feed applications and a source of pigment for coloring farmed salmon species. Igene provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors. The company also provides analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. Within animal nutrition, the Company focus is to deliver astaxanthin to the fish feed market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 29 Jul 1986
- Employees
- 18
Leadership
Pay as last reported
- Mr. Michael KimelmanChairman of the Board, since 1991
- Stephen HiuPresident, Chief Technical Officer, Treasurer, Director of R&D, Director, since 1990$192,615
- Mr. Thomas KempnerVice Chairman of the Board
- Edward WeisbergerChief Financial Officer$171,456
- Patrick MonahanVice President, Secretary, Director of Manufacturing, Director, since 1991$168,945
- Mr. Sidney KnafelDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Igene Biotechnology Inc has a strong research and development team comprising highly skilled scientists and experts in the field. This expertise enables the company to generate innovative and high-quality biotechnology products. Additionally, the company has established a robust intellectual property portfolio, protecting its inventions and giving it a competitive advantage in the market.
- The company also benefits from a well-established distribution network, allowing it to effectively reach and serve its target market. Igene Biotechnology Inc has a strong brand reputation and a loyal customer base, which contributes to its overall market presence.
Weaknesses
- One of the weaknesses of Igene Biotechnology Inc is its heavy reliance on a limited number of key customers. This dependency exposes the company to risks such as fluctuations in demand or the loss of a major customer. It should diversify its customer base to reduce this vulnerability.
- Another weakness is the company's current financial situation, which may limit its ability to invest in research and development or expand its operations. It should consider strategies to improve its financial stability and secure additional funding sources.
Opportunities
- Igene Biotechnology Inc can explore opportunities in expanding its product portfolio to cater to emerging market trends and customer demands. For example, it can invest in the development of biotechnology products for personalized medicine or genetic testing, which are growing areas in the healthcare industry.
- The company can also leverage strategic partnerships and collaborations with other biotechnology firms or research institutions to accelerate product development and access new markets. This can lead to increased market share and revenue growth for Igene Biotechnology Inc.
Threats
- One of the threats affecting Igene Biotechnology Inc is intense competition within the biotechnology industry. The presence of established players and new entrants can lead to pricing pressures and reduced market share. The company should continuously monitor the competitive landscape and adapt its strategies accordingly.
- Regulatory hurdles and compliance requirements are also significant threats to Igene Biotechnology Inc. The industry operates in a highly regulated environment, and any changes in regulations or failure to comply with existing ones can have negative consequences for the company's operations and reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.